Agonist News and Research

RSS

Purified components of ginger help asthma patients breathe more easily

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the spicy root also may have properties that help asthma patients breathe more easily.

20 May 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

TWi Pharmaceuticals, Inc. today announced that it has received tentative approval for its Abbreviated New Drug Application for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration.

14 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Synthetic anti-inflammatory substances related to marijuana may help fight HIV infection

HIV, the virus that causes AIDS, is notorious for hiding within certain types of cells, where it reproduces at a slowed rate and eventually gives rise to chronic inflammation, despite drug therapy.

2 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

New official clinical practice guidelines on diagnosis, management of EIB

The American Thoracic Society has released new official clinical practice guidelines on the diagnosis and management of exercise-induced bronchoconstriction, the acute airway narrowing that occurs as a result of exercise.

2 May 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

26 Apr 2013

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome.

25 Apr 2013

Researchers explore new technique to determine the activity of different calcium channels in cancer cells

Two Wayne State University researchers are working on a technique that could lead to easier, faster identification of cancer tumors that can be effectively treated by calcium channel-based therapies.

23 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).

12 Apr 2013

Study suggests drugs prescribed to lower cholesterol may be effective against macular degeneration

A new study raises the intriguing possibility that drugs prescribed to lower cholesterol may be effective against macular degeneration, a blinding eye disease. Researchers at Washington University School of Medicine in St. Louis have found that age-related macular degeneration, the leading cause of vision loss in Americans over 50, shares a common link with atherosclerosis.

3 Apr 2013

Targeting cholesterol metabolism in eye may prevent age-related macular degeneration, says study

Targeting cholesterol metabolism in the eye might help prevent a severe form of age-related macular degeneration (AMD), one of the most common causes of blindness in older Americans, according to indications in a study in mice, which was supported by the National Institutes of Health.

3 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Agonist News and Research

Purified components of ginger help asthma patients breathe more easily

Newer class of diabetes medications may also improve cardiovascular health, researchers report

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Synthetic anti-inflammatory substances related to marijuana may help fight HIV infection

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

New official clinical practice guidelines on diagnosis, management of EIB

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Researchers explore new technique to determine the activity of different calcium channels in cancer cells

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

COPD phase III study by Almirall and Forest Laboratories announces positive results

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Study suggests drugs prescribed to lower cholesterol may be effective against macular degeneration

Targeting cholesterol metabolism in eye may prevent age-related macular degeneration, says study

Adenosine Therapeutics to explore strategic options for Stedivaze

Promising studies for Parkinson's to be presented at 65th AAN meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News